SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Alumis trial of lupus drug fails to meet endpoints

Alumis said its phase 2b trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints, including the goal for overall disease activity improvements.

ALMS

Alumis said its trial of a lupus treatment did not meet its primary or secondary endpoints. The phase 2b study of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet the goal of improving overall disease activity based on various measures.

Related stories